DM
TRIB

Deerfield Management’s Trinity Biotech TRIB Stock Holding History

Deerfield Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-49,200
Closed -$2.89M – 115
2015
Q4 		$2.89M Hold
49,200
– – 0.12% 93
2015
Q3 		$2.81M Sell
49,200
-3,298
-6% -$265K 0.11% 107
2015
Q2 		$4.74M Buy
+52,498
New +$4.55M 0.16% 95

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Deerfield Management's TRIB Position: Q1 2016 in Review

Deerfield Management sold out of Trinity Biotech (TRIB) in Q1 2016, closing a stake of 49,200 shares — an estimated $2.89M sold.

Deerfield Management first reported a position in TRIB in Q2 2015 and held it in 3 quarters. The position peaked at $4.74M in Q2 2015. 79 funds tracked by Wall St. Rank hold TRIB as of Q1 2016.

  • Deerfield Management reported no remaining Trinity Biotech position as of Q1 2016 after selling out during the quarter.
  • Deerfield Management sold 49,200 Trinity Biotech shares in Q1 2016, an estimated $2.89M.
  • Deerfield Management first reported a position in Trinity Biotech in Q2 2015 and held it in 3 quarters.
  • Deerfield Management's Trinity Biotech position peaked at $4.74M in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2016.

Based on Deerfield Management's 13F filing for Q1 2016, filed 16 May 2016.